Oral vaccination of badgers (Meles meles) with BCG and protective immunity against endobronchial challenge with Mycobacterium bovis

Vaccine
Leigh A L CornerE Gormley

Abstract

Eurasian badgers (Meles meles) are a reservoir host of Mycobacterium bovis and are implicated in the transmission of tuberculosis to cattle in Ireland and Great Britain. The development of a vaccine for use in badgers is considered a key element of any long-term sustainable campaign to eradicate the disease from livestock in both countries. The aim of this study was to investigate the protective response of badgers vaccinated orally with Bacille Calmette-Guérin (BCG) encapsulated in a lipid formulation, followed by experimental challenge with M. bovis. A group of badgers was vaccinated by inoculating the BCG-lipid mixture containing approximately 10(8)colony forming units (cfu) of BCG into the oesophagus. The control group was sham inoculated with the lipid formulation only. Thirteen weeks after vaccination all the badgers were challenged with approximately 10(4)cfu of M. bovis delivered by endobronchial inoculation. Blood samples were taken throughout the study and the cell mediated immune (CMI) responses in peripheral blood were monitored by the IFN-gamma ELISA and ELISPOT assay. At 17 weeks after infection all the badgers were examined post-mortem to assess the pathological and bacteriological responses to challenge. All bad...Continue Reading

References

Jul 13, 1996·The Veterinary Record·K Stöhr, F M Meslin
Mar 8, 2005·Preventive Veterinary Medicine·J M GriffinS J More
Jun 15, 2007·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Christl A DonnellyW Ivan Morrison
Jun 6, 2009·Proceedings. Biological Sciences·D M TompkinsB M Buddle

❮ Previous
Next ❯

Citations

Jun 28, 2012·Veterinary Medicine International·Mitchell V PalmerLeigh A L Corner
May 20, 2014·The Veterinary Record·G McGrathS J More
Apr 11, 2013·Epidemiology and Infection·J L HardstaffP C L White
Jun 25, 2013·Preventive Veterinary Medicine·I AznarM C M De Jong
Feb 22, 2012·Comparative Immunology, Microbiology and Infectious Diseases·Philip A RobinsonDarrell A Abernethy
Apr 14, 2011·The Veterinary Journal·Eamonn Gormley, Leigh A L Corner
Nov 6, 2013·Transboundary and Emerging Diseases·E Gormley, L A L Corner
Nov 6, 2013·Transboundary and Emerging Diseases·B M BuddleA Heiser
Feb 22, 2012·Vaccine·W Ray WatersH Martin Vordermeier
Dec 16, 2011·Comparative Immunology, Microbiology and Infectious Diseases·Nazneen SiddiquiJayne Hope
May 6, 2014·The Veterinary Journal·Bryce M Buddle, Geoffrey W de Lisle
Aug 1, 2012·Veterinary Medicine International·Beatriz Beltrán-BeckChristian Gortázar
Feb 7, 2020·Annals of the New York Academy of Sciences·Anna StedmanJorge Gutierrez-Merino
Jun 19, 2020·Pathogens·Ana BalseiroMaría A Risalde
Mar 7, 2020·The Journal of Applied Ecology·Courtney L SchreinerAndrew J Basinski
Feb 9, 2017·Frontiers in Cellular and Infection Microbiology·Mark A ChambersSandrine Lesellier
Oct 24, 2018·Frontiers in Veterinary Science·Mitchell V Palmer, Tyler C Thacker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.